GeneOne Life Science, Inc. 011000.KS Stock
GeneOne Life Science, Inc. Price Chart
GeneOne Life Science, Inc. 011000.KS Financial and Trading Overview
| GeneOne Life Science, Inc. stock price | 2240 KRW |
| Previous Close | 4440 KRW |
| Open | 4450 KRW |
| Bid | 4485 KRW x 0 |
| Ask | 4490 KRW x 0 |
| Day's Range | 4435 - 4520 KRW |
| 52 Week Range | 4105 - 16650 KRW |
| Volume | 313.89K KRW |
| Avg. Volume | 518.64K KRW |
| Market Cap | 348.32B KRW |
| Beta (5Y Monthly) | -1.644863 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 KRW |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
011000.KS Valuation Measures
| Enterprise Value | 330.27B KRW |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 7.8848147 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 7.476 |
| Enterprise Value/EBITDA | -8.014 |
Trading Information
GeneOne Life Science, Inc. Stock Price History
| Beta (5Y Monthly) | -1.644863 |
| 52-Week Change | -58.88% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 16650 KRW |
| 52 Week Low | 4105 KRW |
| 50-Day Moving Average | 5665 KRW |
| 200-Day Moving Average | 7554.05 KRW |
011000.KS Share Statistics
| Avg. Volume (3 month) | 518.64K KRW |
| Avg. Daily Volume (10-Days) | 428.39K KRW |
| Shares Outstanding | 77.58M |
| Float | 70.66M |
| Short Ratio | N/A |
| % Held by Insiders | 7.95% |
| % Held by Institutions | 6.93% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | N/A |
| Trailing Annual Dividend Yield | N/A |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1.2:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -105.80% |
| Operating Margin (ttm) | -105.47% |
| Gross Margin | 9.21% |
| EBITDA Margin | -93.29% |
Management Effectiveness
| Return on Assets (ttm) | -12.53% |
| Return on Equity (ttm) | -24.63% |
Income Statement
| Revenue (ttm) | 44.18B KRW |
| Revenue Per Share (ttm) | 569.18 KRW |
| Quarterly Revenue Growth (yoy) | -38.10% |
| Gross Profit (ttm) | 9.18B KRW |
| EBITDA | -41212661760 KRW |
| Net Income Avi to Common (ttm) | -46740385792 KRW |
| Diluted EPS (ttm) | N/A |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 30.86B KRW |
| Total Cash Per Share (mrq) | 397.98 KRW |
| Total Debt (mrq) | 16.84B KRW |
| Total Debt/Equity (mrq) | 9.53 KRW |
| Current Ratio (mrq) | 1.77 |
| Book Value Per Share (mrq) | N/A |
Cash Flow Statement
| Operating Cash Flow (ttm) | -25575682048 KRW |
| Levered Free Cash Flow (ttm) | -58985209856 KRW |
Profile of GeneOne Life Science, Inc.
| Country | South Korea |
| State | N/A |
| City | Seoul |
| Address | The Pinnacle Gangnam |
| ZIP | 06060 |
| Phone | 82 2 6004 3450 |
| Website | https://www.genels.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the development and contract manufacturing of gene-based-biomedicines. Its products comprise GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company also develops GLS-3000 and GLS-5310 for the treatment of SARS-CoV-2; GLS-5100 to treat VZV-Shingles; and GLS-5140 for the treatment of SFTS. In addition, it is developing GLS-5300, which is in Phase II clinical trial for MERS; GLS-5700 that is in Phase I clinical trial for Zika; and GLS-6150, which is in Phase I clinical trial for treatment of hepatitis C, as well as GLS-6100 that is in pre-clinical stage for hepatitis C. Further, the company, through its subsidiary, VGXI, Inc., engages in the cGMP production of nucleic acid-based products, including DNA plasmids and mRNA. The company was formerly known as VGX International Inc. and changed its name to GeneOne Life Science, Inc. in April 2014. GeneOne Life Science, Inc. was founded in 1976 and is headquartered in Seoul, South Korea.
Q&A For GeneOne Life Science, Inc. Stock
What is a current 011000.KS stock price?
GeneOne Life Science, Inc. 011000.KS stock price today per share is 2240 KRW.
How to purchase GeneOne Life Science, Inc. stock?
You can buy 011000.KS shares on the KSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for GeneOne Life Science, Inc.?
The stock symbol or ticker of GeneOne Life Science, Inc. is 011000.KS.
Which industry does the GeneOne Life Science, Inc. company belong to?
The GeneOne Life Science, Inc. industry is Biotechnology.
How many shares does GeneOne Life Science, Inc. have in circulation?
The max supply of GeneOne Life Science, Inc. shares is 79.83M.
What is GeneOne Life Science, Inc. Price to Earnings Ratio (PE Ratio)?
GeneOne Life Science, Inc. PE Ratio is now.
What was GeneOne Life Science, Inc. earnings per share over the trailing 12 months (TTM)?
GeneOne Life Science, Inc. EPS is 0 KRW over the trailing 12 months.
Which sector does the GeneOne Life Science, Inc. company belong to?
The GeneOne Life Science, Inc. sector is Healthcare.